Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Haller

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Pharmacokinetics|December 6, 2018
Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three TrialsYulan Qi, Kathleen McKeever, Julie Taylor, et al.
Molecular Genetics and Metabolism|February 27, 2018
A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic diseasePaul Harmatz, Chester B Whitley, Raymond Y Wang, et al.
Pharmacogenomics|March 29, 2008
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equationsAlan H B Wu, Ping Wang, Andrew Smith, et al.
Pharmacoepidemiology and Drug Safety|July 17, 2013
Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosisFei Xue, Haijun Ma, Catherine Stehman-Breen, et al.
Psychopharmacology|September 21, 2018
Effect of γ-hydroxybutyrate (GHB) on driving as measured by a driving simulatorEvangelia Liakoni, Delia A Dempsey, Matthew Meyers, et al.
JIMD Reports|September 10, 2019
Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study populationChristine Haller, Wenjie Song, Tricia Cimms, et al.
Clinical Therapeutics|December 10, 2014
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III TrialBecky Schweighardt, Troy Tompkins, Kelly Lau, et al.
Molecular Genetics and Metabolism|October 7, 2014
Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trialChristian J Hendriksz, Roberto Giugliani, Paul Harmatz, et al.
Lancet (London, England)|January 18, 2003
Adverse events associated with dietary supplements: an observational studyMary E Palmer, Christine Haller, Patrick E McKinney, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Pharmacokinetics|December 6, 2018
Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three TrialsYulan Qi, Kathleen McKeever, Julie Taylor, et al.
Molecular Genetics and Metabolism|February 27, 2018
A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic diseasePaul Harmatz, Chester B Whitley, Raymond Y Wang, et al.
Pharmacogenomics|March 29, 2008
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equationsAlan H B Wu, Ping Wang, Andrew Smith, et al.
Pharmacoepidemiology and Drug Safety|July 17, 2013
Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosisFei Xue, Haijun Ma, Catherine Stehman-Breen, et al.
Psychopharmacology|September 21, 2018
Effect of γ-hydroxybutyrate (GHB) on driving as measured by a driving simulatorEvangelia Liakoni, Delia A Dempsey, Matthew Meyers, et al.
JIMD Reports|September 10, 2019
Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study populationChristine Haller, Wenjie Song, Tricia Cimms, et al.
Clinical Therapeutics|December 10, 2014
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III TrialBecky Schweighardt, Troy Tompkins, Kelly Lau, et al.
Molecular Genetics and Metabolism|October 7, 2014
Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trialChristian J Hendriksz, Roberto Giugliani, Paul Harmatz, et al.
Lancet (London, England)|January 18, 2003
Adverse events associated with dietary supplements: an observational studyMary E Palmer, Christine Haller, Patrick E McKinney, et al.
Pageof 2